however, no substantial progress has been made in clinical practice
The U.S., which is among the key markets of GLP-1 drugs biosimilars, has benefited from rising expenditure on healthcare as well as the need for advanced treatments for metabolic diseases
The candidates that exist in 2026 are: clinician judgment (the gold standard, but in short supply), expanded laboratory work (DEXA for body composition, CGM for glycemic patterns, metabolic panels of increasing sophistication), patient-reported priorities (the founder who tells you he cares about muscle is providing useful prior information), and, increasingly, genetics
Ginger and Bitter Herbs Ginger and bitter herbs, such as arugula, artichokes, parsley, cilantro, dandelion, radishes, and any herbs with a pungent, bitter taste